Articles

Poll

Podcasts

Slideshows

Videos

Hepatology

Participants with greater poor sleep and renal function biomarker scores had a 5.45-fold greater risk of developing severe MASLD.


Poor Sleep, Renal Function Linked to Risk of Developing New-Onset MASLD

Alkhouri describes how Agile 3 + and Agile 4 scoring may help address issues with low positive predictive value seen with other noninvasive tests for MASLD fibrosis and cirrhosis.

Naim Alkhouri, MD: Benefit of Agile Scores for Noninvasive Fibrosis, Cirrhosis Testing

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

HbA1c Highly Predicts NAFLD Disease Severity

A new study found physical activity held more weight in the link between the joint exposure of sleep duration, metabolic equivalent of task, and Healthy Eating Index -2015 and MAFLD.

Physical Activity Identified as Critical Factor in Lowering MAFLD Risk

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

Mazen Noureddin, MD, MHSc: MASLD-Related Fibrosis Risk Stratification with FIB-4, VCTE

Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.

Naim Alkhouri, MD: Using AGILE Scoring to Estimate MASLD Fibrosis, Cirrhosis

Results suggest discordance between FIB-4 and liver stiffness measurement for MASLD-related fibrosis risk stratification.

Study Describes Fibrosis Risk Misclassification with FIB-4 Compared to Transient Elastography

Treatment with GLP-1 RAs led to improvements in weight loss, liver function tests, and liver fat in patients with diabetes and MASLD, with hepatic improvements independent of weight loss.

Hepatic Benefits of GLP-1 RAs Are Independent of Weight Loss in MASLD, Diabetes

Noureddin reviews key considerations for starting, monitoring, and discontinuing treatment with resmetirom in patients with noncirrhotic MASH.

Mazen Noureddin, MD, MHSc: Starting, Monitoring Treatment with Resmetirom

New expert panel recommendations outline considerations for initiating and monitoring resmetirom treatment in patients with MASH and moderate fibrosis. 

Considerations for Resmetirom Use, Monitoring in Patients with MASH, Fibrosis

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASH / MASLD